Phaseline

Companies › Taivex Therapeutics

Taivex Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
T-1201 Injection 100 mg Kit–Phase 1Advanced Solid TumorNov 2026
T-1301 Capsules
Multiple kinase inhibitor
–Phase 1Advanced Solid TumorJan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04866641T-1201 Injection 100 mg KitPhase 1Advanced Solid TumorOncologyNov 2026
NCT05156203T-1301 CapsulesPhase 1Advanced Solid TumorOncologyJan 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.